Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03489629 · ClinicalTrials.gov registry record · Phase 2
STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)
A Phase 2 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 2
- Development phase
- 37
- Enrollment target
NCT03489629 is a Phase 2 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 37 participants.
The verdict
NCT03489629, a Phase 2 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 37 participants
- Enrollment target
Study Summary
To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
Interventions
- DRUG Chlorhexidine Gluconate
- DRUG Minocycline
- DRUG Mupirocin
- DRUG Trimethoprim Sulfamethoxazole (TMP/SMX)
- BEHAVIORAL Environmental Decontamination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2018-04-03 |
| Est. Completion | 2026-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03489629
The ClinicalTrials.gov registry entry for NCT03489629 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Chlorhexidine Gluconate is the first listed.
NCT03489629 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03489629 about?
NCT03489629 is a clinical study titled "STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)". To evaluate the micro-biologic efficacy and safety of a streamlined treatment for early onset methicillin-resistant staphylococcus aureus (MRSA) in patients with cystic fibrosis.
What is the current status of trial NCT03489629?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 37 participants. The study started on 2018-04-03. Estimated completion is 2026-01-31.
What interventions are being tested in trial NCT03489629?
The interventions under investigation include: Chlorhexidine Gluconate (DRUG), Minocycline (DRUG), Mupirocin (DRUG), Trimethoprim Sulfamethoxazole (TMP/SMX) (DRUG), Environmental Decontamination (BEHAVIORAL).
Who is sponsoring clinical trial NCT03489629?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.